Clot waveform of APTT has abnormal patterns in subjects with COVID-19.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 03 2021
Historique:
received: 11 07 2020
accepted: 22 02 2021
entrez: 5 3 2021
pubmed: 6 3 2021
medline: 13 3 2021
Statut: epublish

Résumé

In Coronavirus disease 2019 (COVID-19) subjects, recent evidence suggests the presence of unique coagulation abnormalities. In this study, we performed clot waveform analyses to investigate whether specific modulations are observed in COVID-19 subjects. We analyzed the second derivative of the absorbance in routine APTT tests performed using an ACL-TOP system. We observed high frequencies of abnormal patterns in APTT second-derivative curves that could be classified into an early shoulder type, a late shoulder type, or a biphasic type, high maximum first-derivative and second-derivative peak levels, and a low minimum second-derivative peak level in COVID-19 subjects. These modulations were not observed in subjects with disseminated intravascular coagulation. These abnormal patterns are also observed in patients with lupus anticoagulant, hemophilia, or factor IX deficiency. The plasma fibrinogen levels might also be involved in the abnormal APTT waveforms, especially the high maximum first-derivative and second-derivative peak levels. The abnormal patterns in the APTT second-derivative curves appear with highest frequency at around 2 weeks after the onset of COVID-19 and were not associated with the severity of COVID-19. These results suggest the possible presence of a specific abnormal coagulopathy in COVID-19.

Identifiants

pubmed: 33664450
doi: 10.1038/s41598-021-84776-8
pii: 10.1038/s41598-021-84776-8
pmc: PMC7933409
doi:

Substances chimiques

(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II) 0
Organometallic Compounds 0
Triazoles 0
Fibrinogen 9001-32-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5190

Références

Am J Hematol. 2020 Jul;95(7):E156-E158
pubmed: 32267008
J Am Coll Cardiol. 2020 Jul 7;76(1):122-124
pubmed: 32387623
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
J Thromb Haemost. 2020 Sep;18(9):2215-2219
pubmed: 32668058
Clin Appl Thromb Hemost. 2018 Jul;24(5):764-770
pubmed: 28884611
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
J Hematol Oncol. 2020 Sep 4;13(1):120
pubmed: 32887634
Thromb J. 2020 Sep 7;18:17
pubmed: 32922211
Arterioscler Thromb Vasc Biol. 2020 Dec 3;:ATVBAHA120315547
pubmed: 33267656
Int J Lab Hematol. 2017 Dec;39(6):561-568
pubmed: 28876509
J Thromb Thrombolysis. 2020 Oct 24;:
pubmed: 33098540
Biomed Res Int. 2020 Nov 6;2020:9126148
pubmed: 33204727
N Engl J Med. 2020 Jul 16;383(3):288-290
pubmed: 32369280
Blood. 1996 Mar 15;87(6):2292-300
pubmed: 8630390
Thromb Haemost. 2014 Apr 1;111(4):598-609
pubmed: 24573248
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Lab Haematol. 2002 Dec;24(6):321-7
pubmed: 12452811
Blood Coagul Fibrinolysis. 2021 Jan 12;:
pubmed: 33443926
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Thromb Res. 2021 Jan;197:20-23
pubmed: 33161283
Int J Lab Hematol. 2011 Feb;33(1):67-78
pubmed: 20649909
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Viruses. 2019 Jan 16;11(1):
pubmed: 30654597
Blood Coagul Fibrinolysis. 2016 Jun;27(4):474-6
pubmed: 26523912
J Infect Dis. 2020 Nov 9;222(11):1789-1793
pubmed: 32812049
Sci Rep. 2021 Jan 19;11(1):1793
pubmed: 33469056
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
PLoS One. 2016 Jun 29;11(6):e0157835
pubmed: 27355205
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Thromb J. 2019 Jun 28;17:12
pubmed: 31297038
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143

Auteurs

Takuya Shimura (T)

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Makoto Kurano (M)

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. kurano-tky@umin.ac.jp.

Yoshiaki Kanno (Y)

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.

Mahoko Ikeda (M)

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.

Koh Okamoto (K)

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.

Daisuke Jubishi (D)

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.

Sohei Harada (S)

Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.

Shu Okugawa (S)

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.

Kyoji Moriya (K)

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.

Yutaka Yatomi (Y)

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH